

Radox releases bladder cancer array

March 2024—Radox has released its female bladder cancer array, designed to help clinicians stratify patients presenting with hematuria. The array detects interleukin-12p70, interleukin-13, midkine, and clusterin from a single urine sample to determine an individual's biomarker risk score. A person's risk for developing bladder cancer is determined by combining the biomarker risk score with clinical risk scores generated using the company's algorithms.

The product features the company's biochip array technology, which works by combining a panel of related biomarkers in a single biochip with one set of reagents, controls, and calibrators.

[Radox Laboratories](#), +44 (0) 28 9442 2413